RVRodrigo Vincenzi

Rodrigo Vincenzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rodrigo Vincenzi has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rupture of Hepatic Hemangioma Following Living Donor Liver Transplantation: A Case Report

    by João Seda Neto, Nathalia Porto Rangel Travassos, Carolina M. Costa, Renata Pugliese, Marcel R. Benavides, Karina Roda, Rodrigo Vincenzi, Debora Puzzi Fernandes, Eduardo A. Fonseca

    Background: Hepatic hemangiomas are common benign liver tumors, typically asymptomatic with a low complication rate in liver transplantation (LT). However, post‐transplant rupture, though rare, can result in significant morbidity. This report describes the rupture of a small hepatic hemangioma in a liver graft following pediatric living donor liver transplantation (LDLT). Case Report: An 11‐month‐old boy with biliary atresia underwent LDLT using a left lateral segment from his healthy mother. Preoperative imaging revealed a 2x3 cm hemangioma in Segment III of the donor's liver. Post‐transplant, the child experienced significant bleeding 4 h after surgery, leading to hemodynamic instability and a drop in hemoglobin. Re‐exploration revealed a large hematoma and rupture at the hemangioma site. Additional resection of the hemangioma and hematoma was performed. The child recovered after a prolonged ICU stay and remains well after 8 years of follow‐up. Discussion: Hepatic hemangiomas are generally asymptomatic, but rupture post‐transplant can lead to severe complications. There is no standardized approach for managing hemangiomas in liver grafts. This case highlights the need for careful evaluation of lesion size, location, and potential vascular and biliary implications in donor selection. Further research is needed to define optimal management strategies for liver graft hemangiomas. Conclusion: While rare, hepatic hemangiomas in liver grafts require careful evaluation, with further studies needed to establish management protocols.


  • Nutritional management and outcomes of malnourished children under 2 years with intestinal failure

    by Estela Cristina Pavanelli, Joao Seda Neto, Beatriz Camilo Farah, Roberta Luiza Longo, Natália Canale Person, Catiana Mitica Gritti, Carine Dias Ferreira de Jesus, Camila Mascarenhas Teixeira de Carvalho, Massami Hayashi, Catherina Oliveira Gameiro, et al.

    Objective: This study aimed to assess the evolution of nutritional status, parenteral nutrition (PN) composition, and PN dependence index (PNDI) in children under 2 years old with intestinal failure (IF) and malnutrition.Methods: This retrospective cohort included patients admitted between November 1, 2016, and August 31, 2021, with IF, age ≤24 months, and weight‐for‐age (Wt/A) <−2 standard deviation with a follow‐up of 12 months. Data collected included demographic, anthropometric, biochemical, and nutritional information. The PNDI was compared between enteral autonomy (EA) and nonenteral autonomy (non‐EA) groups.Results: Thirty patients (16 males, 53.33%) were included, and short bowel syndrome (SBS) was the leading cause of IF (n = 27, 90%). The mean age at admission was 7.23 ± 3.90 months, and 36.66% of the patients had a conjugated bilirubin (CB) level >2 mg/dL; 87% had a Wt/A z‐score <−3 and 90% had a height‐for‐age (Ht/A) z‐score <−3. At 5 months, the mean Wt/A z‐score improved to −1.82. At admission, median protein, lipid, and glucose intake on PN were 3, 1.6, and 17.27 g/kg/day, respectively. In the PNDI analysis, the EA group had a mean index of 141% versus 158% for the non‐EA group at admission, with no statistical differences. From the sixth month onward, the EA group showed a significantly lower PNDI (50% vs. 108% for non‐EA patients; p = 0.032). Both groups demonstrated adequate nutritional recovery.Conclusion: Adequate multidisciplinary care can reverse severe malnutrition, and the PNDI may be a predictor of EA.


  • Anterior hepatic resection: A simple and safe technique for reducing the antero‐posterior diameter of the liver graft for small pediatric recipients

    by João Seda Neto, Carolina Magalhães Costa, Fabio Payão Pereira, Renata Pugliese, Nathalia P. Travassos, Caio M. Oliveira, Rodrigo Vincenzi, Marcel R. Benavides, Karina Roda, Mário Kondo, et al.

    Background: The techniques involved in neonatal and infantile transplantation require approaches that can sculpt a left lateral segment (LLS) to the right shape and size and avoid large‐for‐size syndrome. The aim of this article is to describe the anterior hepatic resection (AHR) of the LLS in pediatric LDLT.Methods: A retrospective anatomical study of preoperative image studies, description of the technique for AHR, and short‐term results.Results: The AHR was performed in eight cases. All donors were male, with average age, BW, and BMI of 28.3 ± 5.9 years, 74.2 ± 9.3 kg, and 24.3 ± 2.6 kg/m2, respectively. Donors were discharged at an average of 3.6 ± 0.8 days. The median recipient age and BW at transplantation were 6.9 (2.7 to 11) months and 5.9 (3.9 to 8) kg, respectively, and the recipient‐to‐donor body weight ratio (RDBW) was <0.1 in all but one case. The mean percentage reduction in graft weight and in the antero‐posterior diameter were 33.2% ± 5.5% and 38.3% ± 12.6%, respectively. The average (SD) GRWR was 4.8% ± 1.7% before all the resections and 3.5% ± 1.0% after the procedures. Seven patients were primarily closed.Conclusion: After LLS resection, a nonanatomical anterior resection of the LLS was accomplished without hilar vascular dissection to segments II/III. The final liver graft allowed primary abdominal wall closure in all but one patient, with meaningful adjustments in GRWR. AHR proved to be simple, safe, reproducible, and effective in the presented case series.


  • Liver transplantation for hilar inflammatory myofibroblastic tumor: Case report and review of the literature

    by Carolina Magalhães Costa, João Seda Neto, Marcel R. Benavidez, Rodrigo Vincenzi, Karina Roda, Caio Márcio V. Oliveira, Nathália Porto R. Travassos, Luiz Guilherme C. A. de Lima, Fabio Payão Pereira, Eduardo A. Fonseca

    Background: Inflammatory myofibroblastic tumors (IMTs) of the liver are rare neoplasms. These tumors are difficult to distinguish from other neoplasms by radiological examination, have uncertain evolution, and there is no consensus on the treatment of these lesions. Hilar tumors can involve the portal vein, hepatic artery, bile duct, and spread to the branches of the portal triad, causing obstructive symptoms, occlusive phlebitis, and portal hypertension. Thus, liver transplantation (LT) is an excellent alternative for locally advanced hilar tumors, since it ensures complete tumor resection with free margins.Methods/Results: We present a literature review and a case report showing a 3‐year‐old boy with liver IMT invading the hepatic hilum and inferior vena cava, who underwent a successful living donor liver transplantation that required portal vein and vena cava replacement.Conclusion: The incidence of hilar IMTs is low and there is no well‐established standard treatment. Liver transplantation for a hilar tumor with vascular invasion was acceptable in this case because the radically of the surgery was the key for the cure, and because the tumor was benign in nature.


  • Open Access

    Living Donor Liver Transplantation as a Backup Procedure: Treatment Strategy for Hepatocellular Adenomas Requiring Complex Resections

    by Eduardo A. Fonseca, Flavia Feier, Rodrigo Vincenzi, Helry L. L. Candido, Rodrigo L. Azambuja, Fabio Payao, Marcel R. Benavides, Karina M. O. Roda, Katia M. R. Leite, Cristiane M. F. Ribeiro, et al.

    Background & Aims. The most dangerous complications of hepatocellular adenomas are hemorrhage and malignant transformation, both of which require surgical treatment. The surgical treatment strategy for patients with benign large or central tumors is challenging because complex liver resections are required. The strategy of using a live donor as a backup procedure is described in this series. Methods. We present a series of three patients with large hepatocellular adenoma lesions showing a central location, for which the living donor liver transplantation strategy was used as a backup procedure. Results. Hepatocellular adenoma was confirmed by biopsy in all patients. Surgical resection was indicated because of the patients' symptoms and lesion size and growth. All patients had a lesion that was central or in close contact with major vessels. The final decision to proceed with the resection was made intraoperatively. A live donor was prepared for all three patients. Two patients underwent portal vein embolization associated with extended hepatectomy, and a total hepatectomy plus liver transplantation with a living donor was performed in one patient. All patients had good postoperative outcomes. Conclusions. In the treatment of hepatocellular adenomas for which complex resections are necessary and resectability can only be confirmed intraoperatively, surgical safety can be improved through the use of a living donor backup. Center expertise with living donor liver transplantation is paramount for the success of this approach.


  • Open Access

    Pediatric liver transplantation activity in a high‐volume program during the COVID‐19 pandemic in Brazil

    by Eduardo A. Fonseca, Flavia Feier, Renata Pugliese, Aline F. Freitas, Gilda Porta, Irene Miura, Vera Baggio, Mario Kondo, Marcel Benavides, Rodrigo Vincenzi, et al.

    Background: The impact of the COVID pandemic on liver transplant (LT) programs varied among countries. Few data are available about that impact in pediatric liver transplant (PLT) programs. This study aimed at comparing the data of our program in Brazil (2019 vs. 2020).Methods: Retrospective cohort study.Results: One hundred and seventy‐four PLT were performed in the period (93% living donors). Patients were divided into two groups according to the LT date: pre‐COVID‐19 period (march/2019–February/2020) and COVID‐19 period (March/2020–February 2021). In the pre‐COVID‐19 period, 97 LTs were performed, and 77 LTs were performed in the COVID‐19 period. Patients in the COVID‐19 period were younger (10.9 months vs. 16 months, p 0.009), had higher PELD scores (15 vs. 14, p 0.04), more ascites (66.2 vs. 51.5%, p 0.03), and more frequently hospitalized before LT (27.3 vs. 17.5%). However, there was no difference in post‐LT complications, retransplantation nor survival rates. Six (6.2%) patients from pre‐COVID‐19 period were COVID positive at a median of 15.5 months (14–17.5), and 6 (7.8%) patients from COVID‐19 period were COVID positive at a median of 3 months (20 days–6 months) from LT. There was neither mortality nor complications in those patients. Four (33%) were hospitalized, and one had prolonged intubation. Four (33%) were asymptomatic, 4 (33%) had upper airways symptoms, and the remaining had gastrointestinal symptoms.Conclusion: Overall, PLT was not affected during COVID‐19 period. Even though patients from COVID‐19 period were sicker, there was no significant impact in LT outcomes. All the recipients who tested positive for COVID had a favorable outcome.


  • Current Practice in Immunosuppression in Pediatric Liver Transplantation

    by Rodrigo Vincenzi, Eduardo A. Fonseca, Karina M. O. Roda, Paulo Chapchap, João Seda Neto

    The last decades have witnessed a significant improvement in the field of pediatric liver transplantation (LT), resulting in longer patient and graft survival; adequate graft selection, surgical refinement, the use of live donors and optimal postoperative care are among the reasons why pediatric recipients are living longer. With this new condition, pediatric recipients are now more exposed to the deleterious effects of immunosuppression, including metabolic, infectious and neoplastic complications, nephrotoxicity and neumtoxicity. Due to all those particularities, the approach to avoid overimmunosuppression or underimmunosuppression may be more difficult in children than in adult recipients. Moreover, pediatric recipients are exposed to growth issues and specific problems during adolescence, like nonadherence to immunosuppressive therapy. This article highlights the current immunosuppressive strategies for pediatric liver transplant recipients.


  • Pancreas‐preserving duodenectomy after living donor liver transplantation for invasive cytomegalovirus disease

    by Rodrigo Vincenzi, Eduardo A. Fonseca, Paulo Chapchap, Marcel C. C. Machado, Karina M. O. Roda, Helry L. Candido, Marcel R. Benavides, Marco A. D'ASsuncao, Rogerio C. Afonso, Plinio Turine, et al.

    CMV infection plays an important role in the postoperative course following solid organ transplantation. We present the case of an 11‐year‐old male patient who underwent LDLT due to severe hepatopulmonary syndrome and biliary cirrhosis. Four weeks after LDLT, he developed persistent GI bleeding and was subjected to repeated endoscopic treatment and radiological arterial embolization to stop the bleeding from duodenal ulcers. Diagnostic workup was negative for CMV disease. Because the bleeding persisted, surgical treatment was indicated, and a pancreas‐preserving duodenectomy was performed. Immunohistochemical staining of the surgical specimen demonstrated diffuse endothelial infiltration by CMV. Despite ganciclovir treatment, the patient developed new erosions in the jejunal mucosa and melena; ganciclovir was discontinued, and foscarnet was started, resulting in clinical improvement and the cessation of bleeding. This case highlights the technical aspects of performing a complex upper GI resection in a patient recently subjected to LDLT, taking care to avoid injury to the previous liver graft anastomosis and restore GI continuity. Moreover, CMV tissue‐invasive disease compartmentalized in the GI tract may be difficult to diagnose, as indicated by the negative results of antigenemia and PCR assays and endoscopic superficial mucosal biopsies.


  • Living donor liver transplantation for neonatal fulminant hepatitis due to herpes simplex virus infection

    by Rodrigo Vincenzi, Eduardo A. Fonseca, Karina M. O. Roda, Gilda Porta, Helry L. Candido, Marcel R. Benavides, Katia R. M. Leite, Rogerio C. Afonso, Plinio Turine‐Neto, Cristiane M. F. Ribeiro, et al.

    Although rare, ALF caused by disseminated HSV infection is associated with high mortality in the neonatal population. This condition is often diagnosed relatively late due to the absence of specific signs. We present a case involving a neonate with ALF submitted to living donor liver transplantation without a prior diagnosis. The patient had no skin or mucosal lesions, and IgM serology was negative for HSV‐1 and HSV‐2. Immunohistochemical staining of the liver explant was positive for herpes virus infection, and the patient subsequently received antiviral drug treatment, with a good outcome. Due to organ shortages and the rarity of the aforementioned condition, LT has seldom been reported for the treatment of ALF caused by herpes virus infection; however, LT may be the only option for neonates with fulminant hepatitis. The use of living donors in an urgent scenario is well established in Eastern countries and safely applicable for pediatric patients with ALF.